News
Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. BeOne Medicines Ltd.
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...
Following an unprecedented AI chip demand, NVIDIA recently became the first company to reach a market capitalization of $4 ...
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing ...
NRI PULSE STAFF REPORT The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are ...
Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in young children.
Acute Pain Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current acute pain marketed drugs and ...
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain ...
Studies are now underway that could help Journavx win additional FDA approvals for some kinds of chronic pain. Vertex says it is specifically studying Journavx in patients with diabetic peripheral ...
Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results